Vitrakvi and Dizziness aggravated - a phase IV clinical study of FDA data

Summary:

Dizziness aggravated is reported as a side effect among people who take Vitrakvi (larotrectinib), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Synthroid, and have Breast cancer.

The phase IV clinical study analyzes which people have Dizziness aggravated when taking Vitrakvi. It is created by eHealthMe based on reports of 594 people who have side effects when taking Vitrakvi from the FDA, and is updated regularly.

What is Vitrakvi?

Vitrakvi has active ingredients of larotrectinib. eHealthMe is studying from 594 Vitrakvi users. Check the latest studies of Vitrakvi.

What is Dizziness aggravated?

Dizziness aggravated is found to be associated with 2,803 drugs and 974 conditions by eHealthMe. Check the latest studies of Dizziness aggravated.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 28, 2026

594 people reported to have side effects when taking Vitrakvi.
Among them, 43 people (7.24%) have Dizziness aggravated.

Could Vitrakvi cause Dizziness aggravated?

Among these 43 people:

How long have people been on Vitrakvi when they have Dizziness aggravated? *

What is the gender of people who have Dizziness aggravated when taking Vitrakvi? *

female: 51.22 %
male: 48.78 %

What is the age of people who have Dizziness aggravated when taking Vitrakvi? *

What are other drugs people take besides Vitrakvi? *

Synthroid: 2 people, 4.65%
Gabapentin: 1 person, 2.33%

What are other side effects people have besides Dizziness aggravated? *

Fatigue (feeling of tiredness): 14 people, 32.56%
Nausea (feeling of having an urge to vomit): 9 people, 20.93%
Neuropathy Peripheral (surface nerve damage): 7 people, 16.28%
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 6 people, 13.95%
Pain: 5 people, 11.63%
Hepatic Enzyme Increased: 5 people, 11.63%
Peripheral Swelling: 5 people, 11.63%
Muscle Aches (muscle pain): 5 people, 11.63%
Muscle Spasms (muscle contraction): 4 people, 9.30%
Constipation: 4 people, 9.30%

What are the existing conditions these people have? *

Oesophageal Carcinoma (cancer tumour of oesophagus): 4 people, 9.30%
Breast Cancer: 4 people, 9.30%
Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue): 3 people, 6.98%
Thyroid Cancer: 3 people, 6.98%
Constipation: 2 people, 4.65%
Gastrointestinal Stromal Tumor: 2 people, 4.65%
Hepatic Cancer Metastatic (liver cancer - metastatic): 2 people, 4.65%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 4.65%
Tumor: 2 people, 4.65%
Salivary Gland Cancer: 2 people, 4.65%

* Approximation only. Some reports may have incomplete information.

Do you take Vitrakvi and have Dizziness aggravated?

- Check whether Dizziness aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Vitrakvi:

Vitrakvi (594 reports)

Browse all side effects of Vitrakvi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dizziness aggravated:

Dizziness aggravated (2,803 drugs)

Browse all the conditions that are associated with Dizziness aggravated:

Dizziness aggravated (974 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on larotrectinib (the active ingredients of Vitrakvi) and Vitrakvi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.